Renovaro Bilan de santé

Santé financière contrôle des critères 2/6

Renovaro possède un total de capitaux propres de $98.1M et une dette totale de $2.7M, ce qui porte son ratio d'endettement à 2.8%. Son actif total et son passif total sont $121.8M et de $23.7M.

Informations clés

2.8%

Ratio d'endettement

US$2.71m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$220.57k
Fonds propres	US$98.09m
Total du passif	US$23.75m
Total des actifs	US$121.83m

Mises à jour récentes de la santé financière

Recent updates

Enochian stock climbs on US patent for oncology platform

Oct 17

Enochian BioSciences discovers two sets of altered animal data in two of its studies

Jul 01

Enochian Biosciences shares skyrocket after FDA accepts Pre-IND request for HIV treatment

Jun 14

Do Insiders Own Lots Of Shares In Enochian Biosciences, Inc. (NASDAQ:ENOB)?

Feb 14

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de RENB ( $1.9M ) ne couvrent pas ses passifs à court terme ( $23.0M ).

Passif à long terme: Les actifs à court terme de RENB ( $1.9M ) dépassent ses passifs à long terme ( $710.3K ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de RENB ( 2.5% ) est considéré comme satisfaisant.

Réduire la dette: Le ratio d'endettement de RENB est passé de 0% à 2.8% au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: RENB dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: RENB dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 6 % chaque année

Renovaro Bilan de santé

Santé financière contrôle des critères 2/6

Informations clés

Mises à jour récentes de la santé financière

Renovaro Inc. announced delayed annual 10-K filing

Renovaro Receives Deficiency Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

Renovaro Biosciences Inc. announced delayed annual 10-K filing

Enochian Biosciences Inc. Receives Non-Compliance Letter from Nasdaq

Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for Period Ended September 30, 2022

Enochian Biosciences, Inc. announced delayed 10-Q filing

Recent updates

Renovaro Inc. Announces CEO Changes

Renovaro Inc. announced delayed annual 10-K filing

Renovaro Receives Deficiency Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

Renovaro Inc. Announces Geert Kazemier, MD, PhD, as the New Chairman of its Scientific Advisory Board

Renovaro Inc. Announces Board Changes

Renovaro Biosciences Inc. (NasdaqCM:RENB) completed the acquisition of GEDi Cube Intl Ltd.

Renovaro Biosciences Inc. Appoints Avram Miller as Board of Directors

Renovaro Biosciences Inc. Appoints Leni Boeren and Ruud Hendriks as Independent Directors

Renovaro Biosciences Inc. announced delayed annual 10-K filing

Renovaro Biosciences Inc. (NasdaqCM:RENB) signed a letter-of-intent to acquire GEDi Cube Intl Ltd.

Enochian Biosciences Inc. Receives Non-Compliance Letter from Nasdaq

New major risk - Share price stability

Enochian Biosciences Inc.(NasdaqCM:ENOB) dropped from Russell Small Cap Comp Value Index

Enochian Biosciences Inc. Announces That Its Cancer Platform Remains on Track for Trials in Humans Following FDA Review

Enochian Biosciences Inc., Annual General Meeting, Jun 22, 2023

Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for Period Ended September 30, 2022

Enochian Biosciences, Inc. announced delayed 10-Q filing

Enochian Biosciences Receives Notice from Nasdaq for Not Filing Form 10-K

Enochian stock climbs on US patent for oncology platform

Enochian Biosciences, Inc. announced delayed annual 10-K filing

Rosen Law Firm Encourages Enochian Biosciences Investors to Secure Counsel Before Important September 26 Deadline in Securities Class Action

Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Enochian Biosciences Inc. of Class Action Lawsuit and Upcoming Deadline

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Enochian Biosciences, Inc

Johnson Fistel, LLP Announces That A Class Action Lawsuit Commence on Behalf of Investors of Enochian Biosciences Inc

Enochian BioSciences discovers two sets of altered animal data in two of its studies

Is Enochian Biosciences (NASDAQ:ENOB) Using Debt Sensibly?

High number of new directors

Enochian BioSciences Appoints Dr. François Binette, Ph.D. as Executive Vice President for Research and Development

Enochian Biosciences, Inc. Announces Appointment of Greg Duczynski as Senior Vice President for Clinical Operations

High number of new directors

Enochian Biosciences, Inc. Announces Resignation of Carl Sandler as Member of the Board of Directors

Enochian Biosciences (NASDAQ:ENOB) Has Debt But No Earnings; Should You Worry?

Enochian Biosciences, Inc., Annual General Meeting, Mar 14, 2022

Enochian Biosciences (NASDAQ:ENOB) Has Debt But No Earnings; Should You Worry?

Enochian Biosciences, Inc. Announces Its Successful Completion of FDA Pre-IND for A Potential Cure for Hepatitis B Virus Infection

Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential Cure for Hepatitis B Virus Infection

Enochian BioSciences Announces Scientific Presentation of Elimination of HBV in Mice with No Evident Toxicity

Enochian Biosciences, Inc.(NasdaqCM:ENOB) dropped from Russell 3000E Value Index

Enochian Biosciences: A Follow Through For An HIV Cure

Enochian BioSciences, Inc. Announces FDA Acceptance of Pre-IND Request for Potential HIV Cure

Enochian Biosciences shares skyrocket after FDA accepts Pre-IND request for HIV treatment

New 90-day high: US$4.51

Do Insiders Own Lots Of Shares In Enochian Biosciences, Inc. (NASDAQ:ENOB)?

Enochian Biosciences, Inc., Annual General Meeting, Mar 05, 2021

New 90-day high: US$3.51

New 90-day low: US$3.02

New 90-day low: US$3.17

New 90-day low: US$3.40

New 90-day low - US$3.59

Enochian Biosciences, Inc.(NasdaqCM:ENOB) dropped from Russell 3000 Growth Index

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines